A Phase 2, Open-Label, Dose-Escalation Study in Subjects With Pulmonary Arterial Hypertension, (PAH, WHO Group 1) and Pulmonary Hypertension Secondary to Idiopathic Pulmonary Fibrosis, (PH-IPF WHO Group 3) Using Inhaled GeNOsyl.

Trial Profile

A Phase 2, Open-Label, Dose-Escalation Study in Subjects With Pulmonary Arterial Hypertension, (PAH, WHO Group 1) and Pulmonary Hypertension Secondary to Idiopathic Pulmonary Fibrosis, (PH-IPF WHO Group 3) Using Inhaled GeNOsyl.

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Sep 2016

At a glance

  • Drugs Nitric oxide (Primary)
  • Indications Idiopathic pulmonary fibrosis; Pulmonary arterial hypertension; Pulmonary hypertension
  • Focus Adverse reactions
  • Acronyms PHiano
  • Sponsors GeNO LLC
  • Most Recent Events

    • 16 Sep 2016 Status changed from recruiting to completed.
    • 09 Jun 2016 Planned number of patients changed from 75 to 54.
    • 31 Jul 2015 Planned End Date changed from 1 Aug 2013 to 1 May 2016, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top